0956 ET - Moderna posts revenue of $145 million in 2Q, up about 2% from last year. JPMorgan analysts point out, though, that the company's Covid-19 vaccine business is heavily weighted toward the back half of the year. "We do not expect significant focus on this quarter's top-line results specifically," they say in a research note. As for the company's pipeline, its new norovirus vaccine missed expectations in an ongoing late-stage trial, and Moderna anticipates potential approval of its new seasonal influenza vaccine on August 5th. "This would represent Moderna's fifth approved product, though we think it will take more to set the company on a new trajectory," the analysts say. Moderna is up 1%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.